Wire News
St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
Results of a study by investigators at St. Jude Children’s Research Hospital provide strong evidence for why the targeted therapy drug, imatinib, or Gleevec™, which has revolutionized the treatment of chronic myelogenous leukemia, (CML) is often unable to ...
Source:
St. Jude Children's Research Hospital
Wednesday, August 29, 2007